U.S. markets closed

National Research Corporation (NRC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
49.06-0.23 (-0.47%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close49.29
Bid49.00 x 800
Ask49.81 x 800
Day's Range48.02 - 49.70
52 Week Range42.41 - 60.62
Avg. Volume35,039
Market Cap1.248B
Beta (5Y Monthly)0.64
PE Ratio (TTM)36.34
EPS (TTM)1.35
Earnings DateAug 02, 2021 - Aug 06, 2021
Forward Dividend & Yield0.48 (0.98%)
Ex-Dividend DateApr 16, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
3% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • NRC Health Announces Top 10 Winners of the 2021 Customer Approved and Employee Approved Awards

    NRC Health Announces Top 10 Winners of the 2021 Customer Approved and Employee Approved Awards

    Leading senior living organizations honored for dedication and commitment to care amid the ongoing coronavirus pandemicLINCOLN, Neb., May 10, 2021 (GLOBE NEWSWIRE) -- NRC Health, the leading provider of in-depth customer insights in healthcare, today announced the winners of its third annual 2021 Customer Approved and Employee Approved Awards. These awards recognize senior living organizations across the country for delivering exceptional customer and employee experiences. Five independent living, assisted living and skilled nursing facilities were selected in each category, with two organizations earning an award in both categories. The COVID-19 pandemic has had an unimaginable impact on the healthcare industry, especially for the senior living community. As the industry adapts and vaccines rollout, healthcare systems are continuing to innovate in order to best support their patients, including for the aging population who need extra support. To commend these efforts, NRC Health named the top leaders in the sector who are providing the best care experiences for their patients and for having a committed workforce dedicated to the holistic care journey. “This past year has been incredibly difficult for everyone but even in light of these hardships, healthcare systems from all over the nation have made the care experience a priority for their patients and residents,” said Helen Hrdy, Chief Growth Officer at NRC Health. “We are incredibly moved by the dedication these winning organization have made towards the health and well-being of both their patients and their staff. We applaud them today and every day for what they do for the people they serve.” Winners of the Customer Approved Awards were selected based on performance ratings received from family and residents while winners of the Employee Approved Awards are based on feedback given by employees – all information collected through organizational outreach distributed by NRC Health. Winning facilities were then selected based on strong Net Promoter Scores (NPS), one of the most reliable measures of satisfaction and a high-validity proxy measure for loyalty. The full list of award winners is available for download on the NRC Health website. About NRC HealthFor more than 40 years, NRC Health (NASDAQ: NRC) has been committed to achieving humanunderstanding and bringing healthcare organizations closer to their customers than ever before by illuminating and improving the key moments that define an experience and build trust. Guided by their uniquely empathic heritage, proprietary methods, skilled associates, and holistic approach, NRC Health helps its customers design experiences that exceed expectations, inspire loyalty, and improve well-being among patients, residents, physicians, nurses, and staff. For more information, write to info@nrchealth.com, or visit www.nrchealth.com. Press Contact Jennifer LylePublic Relations for NRC Healthnrchealth@barokas.com

  • National Research Corporation Announces First Quarter 2021 Results

    National Research Corporation Announces First Quarter 2021 Results

    LINCOLN, Neb., May 04, 2021 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ: NRC) today announced results for the first quarter of 2021. As we emerge from the impact of COVID-19, our focus continues on increasing revenue growth rate and enabling human understanding for the clients we serve. Our primary emphasis is on our organic growth levers of increasing revenue from our core offerings within our existing client base, as well as adding new clients to increase market share. As a result, revenue from our Voice of the Customer offerings increased by 19% in the first quarter of 2021 compared to 2020, and we continued our momentum of winning new clients, including Wake Forest Baptist Health, San Francisco Health Network and UC San Diego Health. In the first quarter we also executed on our M&A growth strategy by acquiring the intellectual property of PatientWisdom, whose incremental capabilities will be introduced later this year to add significant value to our clients. We have adopted a capital allocation strategy that we expect will leverage our available liquidity, along with our continued strong free cash flow to support additional M&A activity, as well as provide returns to shareholders through our dividends. Financial Results (Q1 2021 compared to Q1 2020): Total Recurring Contract Value growth of 6% to $149.5 millionRevenue increased 5% to $35.5 millionOperating Income increased 7% to $12.0 million Continued demand for our solutions resulted in a 6% increase in Total Recurring Contract Value in the first quarter of 2021 compared to the first quarter 2020. We believe our solutions are highly differentiated in our client’s eyes against competitive offerings from firms outside of the healthcare industry and legacy vendors within as we continue to add new clients. We believe that every added client deepens our moat and brings additive value to all current partners through the network effect. First quarter 2021 revenue was $35.5 million, an increase of 5% over first quarter 2020. The increase is net of a $605,000 decrease in conference revenue in the first quarter 2021 due to the timing of conferences and a virtual format in 2021 compared to a live format in 2020. Consolidated operating income for the first quarter 2021 was $12.0 million or a 7% increase over the same period last year. Total operating expenses of $23.4 million for the first quarter 2021 increased by 3% compared to the first quarter 2020 total operating expenses of $22.7 million. Direct expenses decreased to $11.9 million for the first quarter 2021, compared to $12.5 million for the first quarter 2020. Direct expenses as a percentage of revenue decreased to 34% in the first quarter 2021 compared to 37% in the first quarter 2020 due to decreases in variable expenses of $103,000 and fixed expenses of $502,000. Variable expenses decreased due to less postage, printing, and paper costs, partially offset by higher contracted services primarily resulting from changes in survey methodologies and decreased conference expenses due to the timing and format of conferences. Fixed expenses decreased primarily as a result of decreased contracted services and lower travel and meal costs due to restricted travel associated with COVID-19, partially offset by increased salary and benefit costs. Selling, general and administrative expenses increased to $9.5 million for the first quarter 2021, compared to $8.7 million for the same period in 2020, primarily due to increases in software and platform hosting expenses, higher contracted services, increased salary and benefit costs, higher accounting and legal costs and additional building lease costs. These were partially offset by lower travel and meals costs due to restricted travel associated with COVID-19. Selling, general and administrative expenses were 27% of revenue for the first quarter 2021, compared to 26% of revenue for the first quarter of 2020. Depreciation, amortization and impairment expense increased to $2.0 million in the first quarter of 2021 compared to $1.4 million in 2020, primarily due to our transformation to a distributed workforce environment which includes building renovations in our headquarters, as well as subleasing a remote office location which resulted in a right-of-use asset impairment and increased depreciation due to shortening the estimated useful lives of certain building assets. Depreciation, amortization and impairment expense was 6% of revenue for the first quarter 2021, compared to 4% of revenue for first quarter of 2020. Other income and expense was $408,000 of other net expense in the first quarter 2021 compared to $176,000 of other net income in first quarter of 2020. This increase in other net expense was primarily due to revaluation on intercompany transactions due to changes in the foreign exchange rate. This was partially offset by decreased interest expense due to the declining balance on our term loan. The Company had an income tax provision of $2.4 million for first quarter 2021 compared to $385,000 tax benefit in 2020 with an effective tax rate of 20% for first quarter 2021 compared to a 3% benefit in 2020. The effective tax rate increased due to decreased tax benefits of $2.8 million from the exercise and vesting of share-based compensation awards and higher state income taxes. Net income for first quarter 2021 was $9.2 million, compared to $11.8 million for the same period last year. Diluted earnings per share decreased to $0.36 for the quarter ended March 31, 2021, from diluted earnings per share of $0.46 for the quarter ended March 31, 2020. For more than 40 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. Our purpose is to enable human understanding by helping our clients to understand the voice of the customer with greater clarity, immediacy and depth. This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2020 and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. In this press release, the statements relating to future M&A activity, future payment of dividends, and the future impact of adding additional clients are forward-looking statements. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information. NATIONAL RESEARCH CORPORATION AND SUBSIDIARY Unaudited Condensed Consolidated Statements of Income (In thousands, except per share data) Three months endedMarch 31, 2021 2020 Revenue $35,464 $33,860 Operating expenses: Direct 11,940 12,546 Selling, general and administrative 9,520 8,749 Depreciation, amortization and impairment 1,984 1,371 Total operating expenses 23,444 22,666 Operating income 12,020 11,194 Other income (expense): Interest income 3 11 Interest expense (432) (465)Other, net 21 630 Total other income (expense) (408) 176 Income before income taxes 11,612 11,370 Income tax provision (benefit) 2,380 (385) Net income $9,232 $11,755 Earnings Per Share of Common Stock: Basic Earnings Per Share $0.36 $0.47 Diluted Earnings Per Share $0.36 $0.46 Weighted average shares and share equivalents outstanding Basic 25,414 24,97 Diluted 25,668 25,725 NATIONAL RESEARCH CORPORATION AND SUBSIDIARY Unaudited Condensed Consolidated Balance Sheets (Dollars in thousands, except share amounts and par value) March 31, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $43,454 $34,690 Accounts receivable, net 14,296 13,923 Income taxes receivable 144 1,235 Other current assets 4,341 4,264 Total current assets 62,235 54,112 Property and equipment, net 11,533 11,726 Goodwill 61,614 57,255 Other, net 11,496 10,330 Total assets $146,878 $133,423 Liabilities and Shareholders’ Equity Current liabilities: Current portion of notes payable $4,113 $4,061 Accounts payable and accrued expenses 4,156 4,279 Accrued compensation 6,622 6,460 Income taxes payable 1,037 -- Deferred revenue 17,614 15,585 Other current liabilities 3,396 1,296 Total current liabilities 36,938 31,681 Notes payable, net of current portion 25,494 26,547 Other non-current liabilities 11,196 10,880 Total liabilities 73,628 69,108 Shareholders’ equity: Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued -- -- Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,850,131 in 2021 and 30,775,154 in 2020, outstanding 25,439,013 in 2021 and 25,390,968 in 2020 31 31 Additional paid-in capital 172,642 171,785 Retained earnings (accumulated deficit) (52,143) (61,375)Accumulated other comprehensive loss, foreign currency translation adjustment (2,343) (2,399)Treasury stock (44,937) (43,727)Total shareholders’ equity 73,250 64,315 Total liabilities and shareholders’ equity $146,878 $133,423 Contact:Kevin R. Karas Chief Financial Officer 402-475-2525

  • If You Like EPS Growth Then Check Out National Research (NASDAQ:NRC) Before It's Too Late
    Simply Wall St.

    If You Like EPS Growth Then Check Out National Research (NASDAQ:NRC) Before It's Too Late

    Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...